Explore

Rapid Read Rapid Read
Research Highlights Impact of Insurance on Cancer Survival Among Young Adults

Research Highlights Impact of Insurance on Cancer Survival Among Young Adults

Recent research underscores the significant role that insurance status plays in cancer survival rates among young adults in the United States. A comprehensive review of scientific literature, involving nearly 470,000 Americans aged 15 to 39 diagnosed with cancer, reveals that those with private health insurance have a survival advantage over those on Medicaid or without insurance. This advantage varies by cancer type, with private insurance reducing the risk of death by 8% for lymphoma and up to 2.5 times for melanoma and other cancers. The study highlights the instability of health coverage for young adults, who often lose insurance when they turn 26 or start jobs without benefits, leaving many uninsured or underinsured. This instability exacerbates the already slower improvements in cancer survival rates for this age group compared to children and older adults.
Rapid Read Rapid Read
Insurance Status Identified as Key Factor in Cancer Survival Rates Among Young Adults

Insurance Status Identified as Key Factor in Cancer Survival Rates Among Young Adults

A recent analysis of nearly 470,000 young Americans diagnosed with cancer reveals that insurance status significantly impacts survival rates. The study found that young adults with private insurance have better survival outcomes compared to those on Medicaid or uninsured. This disparity is attributed to differences in access to specialists, timely treatment, and eligibility for clinical trials. The research highlights the instability of health coverage among young adults, who often face gaps in insurance due to life transitions such as finishing school or starting new jobs.
Trendline Trendline
Vyome to Present Phase 2 Clinical Data on VT-1953 for Malignant Fungating Wounds at AACR 2026

Vyome to Present Phase 2 Clinical Data on VT-1953 for Malignant Fungating Wounds at AACR 2026

Vyome to Present Phase 2 Clinical Data on VT-1953 for Malignant Fungating Wounds at AACR 2026
Trendline Trendline
Delcath Systems' CHEMOSAT System Recognized in European Guidelines for Uveal Melanoma Treatment

Delcath Systems' CHEMOSAT System Recognized in European Guidelines for Uveal Melanoma Treatment

Delcath Systems' CHEMOSAT System Recognized in European Guidelines for Uveal Melanoma Treatment
Trendline Trendline
Delcath Systems' CHEMOSAT System Recognized in European Guidelines for Uveal Melanoma

Delcath Systems' CHEMOSAT System Recognized in European Guidelines for Uveal Melanoma

Delcath Systems' CHEMOSAT System Recognized in European Guidelines for Uveal Melanoma
Trendline Trendline
Vyome to Present Phase 2 Clinical Data on VT-1953 for MFW Treatment at AACR 2026

Vyome to Present Phase 2 Clinical Data on VT-1953 for MFW Treatment at AACR 2026

Vyome to Present Phase 2 Clinical Data on VT-1953 for MFW Treatment at AACR 2026
Rapid Read Rapid Read
Surge in Veterans Affairs Spending Raises Questions on Effectiveness

Surge in Veterans Affairs Spending Raises Questions on Effectiveness

The Department of Veterans Affairs (VA) has seen a significant increase in its budget, reaching over $400 billion last year, nearly half of the Pentagon's baseline budget. This surge in spending has outpaced other federal departments, with a 446% increase from 2004 to 2024. Despite this, questions remain about the effectiveness of the spending in improving veterans' outcomes. The VA's workforce has more than doubled, yet the veteran population has declined. While there have been improvements in some areas, such as a reduction in homeless veterans, challenges persist, including rising veteran suicide rates and issues with mental health care access.
Trendline Trendline
Vyome to Present Phase 2 Data on VT-1953 for Malignant Fungating Wounds

Vyome to Present Phase 2 Data on VT-1953 for Malignant Fungating Wounds

Vyome to Present Phase 2 Data on VT-1953 for Malignant Fungating Wounds
Trendline Trendline
Delcath Systems' CHEMOSAT Hepatic Delivery System Recognized in ESMO-EURACAN Guidelines for Uveal Melanoma

Delcath Systems' CHEMOSAT Hepatic Delivery System Recognized in ESMO-EURACAN Guidelines for Uveal Melanoma

Delcath Systems' CHEMOSAT Hepatic Delivery System Recognized in ESMO-EURACAN Guidelines for Uveal Melanoma
Reuters Reuters
Gilead to buy Germany's Tubulis for up to $5 billion to boost cancer pipeline

Gilead to buy Germany's Tubulis for up to $5 billion to boost cancer pipeline

April 7 (Reuters) - Gilead said on Tuesday it would acquire private Germany-based Tubulis GmbH for up to $5 billion, as the U.S. drugmaker looks to boost its pipeline with a lucrative class of experimental cancer drugs referred to as "guided missiles".
Rapid Read Rapid Read
MSU Researchers Analyze Disparities in U.S. Cancer Mortality Decline

MSU Researchers Analyze Disparities in U.S. Cancer Mortality Decline

Researchers at Mississippi State University's Social Science Research Center, in collaboration with Oak Ridge National Laboratory, have conducted a study on the decline in cancer mortality rates across the U.S. The study, published in the British Journal of Cancer, analyzed data from nearly 3,000 counties between 1981 and 2019. It found that urban and affluent areas experienced more significant declines in cancer deaths compared to rural and less affluent regions. The research highlights the uneven distribution of health improvements and suggests that socioeconomic factors and local health practices play a crucial role in these disparities.
Rapid Read Rapid Read
Japanese Fruit Sarunashi Shows Potential in Preventing Lung Cancer in Mice

Japanese Fruit Sarunashi Shows Potential in Preventing Lung Cancer in Mice

Researchers at Okayama University have identified a small Japanese fruit, Sarunashi (Actinidia arguta), also known as the kiwiberry, as a potential agent in preventing lung cancer. In a study published in the journal Genes and Environment, the fruit's juice was found to reduce lung tumor formation in mice exposed to NNK, a carcinogen related to tobacco. The juice also decreased the number of tumor nodules in the lungs, and its compound isoquercetin demonstrated protective effects. The study suggests that Sarunashi juice may interfere with the initiation and growth of cancer by reducing DNA damage and supporting DNA repair mechanisms. While these findings are promising, clinical trials are necessary to confirm the fruit's efficacy in humans.